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ABSTRACT 
Purpose: To prospectively investigate long-term psychosocial outcomes for women who opted for 
risk-reducing mastectomy (RRM) and/or risk-reducing salpingo-oophorectomy (RRSO). 
 
Methods: Unaffected women from high-risk breast cancer families who had completed baseline 
questionnaires for an existing study and subsequently underwent RRM and/or RRSO, completed 
measures of perceived breast and ovarian cancer risk, anxiety, depression, cancer-related anxiety, 
body image, sexual functioning, menopausal symptoms, use of hormone replacement therapy and 
decision regret three years post-surgery. Outcomes were compared to age- and risk-matched 
controls. 
 
Results: Participants (N=233) were 17 women who had RRM (39 controls), 38 women who had RRSO 
(94 controls) and 15 women who had RRM+RRSO (30 controls). Women who underwent RRM and 
those who underwent RRM+RRSO reported reductions in perceived breast cancer risk and perceived 
breast and ovarian cancer risk respectively, compared to their respective controls. RRM women 
reported greater reductions in cancer-related anxiety compared with both controls and RRSO 
women. RRSO women reported more sexual discomfort than controls and more urogenital 
menopausal symptoms than controls and RRM only women. No differences in general anxiety, 
depression or body image were observed. Regret was associated with greater reductions in body 
image since surgery and more sexual discomfort, although overall regret levels were low. 
 
Conclusions: Women who undergo RRM experience psychological benefits associated with reduced 
breast cancer risk. Although women who undergo RRSO experience some deterioration in sexual and 
menopausal symptoms, they do not regret their surgery decision. It is vital that women considering 
these procedures receive detailed information about potential psychosocial consequences.  
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INTRODUCTION 
The identification of mutations in the BRCA1 and BRCA2 genes associated with an increased risk of 
breast and/or ovarian cancer has provided opportunities to greatly reduce an individual’s risk of 
hereditary breast and/or ovarian cancer (HBOC) through risk-reducing surgery (RRS). In families with 
multiple cases of breast and/or ovarian cancer, risks to age 70 are 72-95% for breast and 28-56% for 
ovarian cancer for BRCA1 mutations [1], and 43-95% and 0-47% for breast and ovarian cancer, 
respectively, for BRCA2 mutations [2]. Although screening options exist for both breast and ovarian 
cancer, many at-risk women consider RRS due to the inability of these options to guarantee early 
detection and consequent cure. Risk-reducing (bilateral) mastectomy (RRM) can reduce the risk of 
breast cancer by approximately 90%, while risk-reducing (bilateral) salpingo-oophorectomy (RRSO) 
reduces the risk of ovarian/fallopian tube (hereafter ‘ovarian’) cancer by approximately 80% and the 
risk of breast cancer by up to 50% [3]. 
While the main advantage of undergoing RRS is the substantial reduction in disease risk, the 
psychological benefits associated with this risk reduction are often cited by women as equally 
important [4-6]. Indeed, research shows that RRS typically leads to reductions in perceived risk of 
developing cancer [7,8] and reductions in cancer-related distress [9,6,10]. Nevertheless, these 
procedures can also have a negative impact on psychosocial, sexual and physical well-being. 
Studies have shown that up to half of women who undergo RRM report a negative impact on 
their sexual relationship [11,12,10], a quarter to one-third report poorer body image and reduced 
feelings of femininity [12,10], and women are more likely to report feelings of regret related to their 
surgery when body image and sexual function are adversely affected by RRM [13]. Despite this, few 
women who undergo RRM report that they regret their surgery decision [14,15,12]. 
Women who undergo RRSO have reported suboptimal sexual functioning and more 
menopausal symptoms, particularly bothersome vaginal symptoms [16], compared to age-matched 
population controls [7]. These symptoms are worse when Hormone Replacement Therapy (HRT) is 
not used [17]. However, a study that compared at-risk women who underwent RRSO (n=29) to a 
control group of women who were also at-risk but opted for screening (n=28) found no difference 
between the groups in sexual functioning, although there was a trend for more menopausal 
symptoms (p=.06) in the surgery group [18]. Thus if risk matched controls are utilized, the impact of 
RRSO on menopausal symptoms appears less. However, these retrospective studies are limited by 
the inherent risk of recall bias and the inability to control for pre-existing differences in psychosocial 
functioning between women who had undergone RRS and controls [7]. 
Prospective evidence for deteriorations in sexual functioning and body image after RRM has 
been mixed. Early studies found no evidence of a negative sexual impact in 79 women who opted for 
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RRM up to 18 months post-surgery [19] and only minor deteriorations in body image in 76 women 
who had RRM up to three years prior [20]. In contrast, Brandberg et al. [21] reported significant 
reductions in body image and sexual pleasure in 90 unaffected women one year after RRM, and 
more recent findings suggest these negative impacts continue at least up to two years following 
RRM [15,22].  
The short follow-up time periods in most of these studies raise the possibility that 
psychosocial outcome data may be influenced by the acute effects of surgery and convalescence, 
and longer-term prospective data are needed. In addition, few studies have compared women who 
underwent surgery to controls and these have typically not controlled for potential confounders. In 
summary, although there is strong evidence that women who undergo RRSO experience an increase 
in menopausal symptoms [7,23], prospective assessment of the long-term psychosocial and 
psychosexual impact of RRSO is lacking. 
The first aim of the current study was to prospectively examine the long-term outcomes 
(three years post-surgery), both positive and negative, of RRS in unaffected women at increased risk 
for HBOC, and compare these with outcomes experienced by controls (rigorously matched on age 
and objective risk of breast cancer) who did not undergo RRS. The outcomes of interest include: a) 
perceived risk of breast and ovarian cancer; b) psychological well-being (anxiety, depression, cancer-
related anxiety); and c) body image, sexual functioning and menopausal symptoms.  
It was hypothesized that women who underwent RRS would experience: 
1) lower perceived risk of breast and/or ovarian cancer, lower general anxiety and depression 
and cancer-related distress; 
2) less favorable body image and/or impaired sexual functioning. 
3)  Further, it was hypothesized that women who underwent RRSO would experience more 
negative menopausal symptoms than women who did not undergo RRSO at 3 year follow-
up, controlling for HRT use.  
The second aim of the study was to examine whether poorer body image and sexual functioning 
would be associated with greater decisional regret three years post-surgery in women who 
underwent RRS. It was hypothesized that this would be the case.  
 
METHODS  
Participants  
Participants in the current study were recruited from among women participating in the Kathleen 
Cuningham Consortium for Research into Familial breast cancer (kConFab) Psychosocial Study. 
kConFab is a registry of Australian and New Zealand families with strong family histories of breast 
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and/or ovarian cancer (www.kconfab.org). The Psychosocial Study recruited unaffected kConFab 
women to complete psychosocial questionnaires and a life event stress interview every three years, 
described in detail elsewhere [24]. Data were collected for this sub-study between April 2005 and 
December 2010. Thus women who underwent RRS three years earlier (April 2002 to December 
2007) were invited to participate. The eligibility criteria for the RRS sub-study were: 
a) Surgery groups: women who had undergone RRM, RRSO, or both (RRM+RRSO), three 
months or more after completing the baseline Psychosocial Study questionnaire assessment. 
Women were excluded if they had these surgeries for other reasons (e.g. cysts) or if they had a 
second RRS within the two years prior to the follow-up assessment.  
b) Control groups: women who had not undergone RRS before or after completing the 
baseline Psychosocial Study questionnaire assessment. Women who had undergone mastectomy or 
oophorectomy for non-prophylactic reasons were excluded. Up to three controls were matched to 
each surgery participant on i) age (+/-5years), ii) objective breast cancer risk (defined below); and iii) 
date of completing the baseline Psychosocial Study assessment (+/-6months).  
 
Procedure 
Eligible kConFab Psychosocial Study participants were invited to participate in the RRS sub-study, 
which involved separate consent and an additional set of self-report questionnaires three years after 
the date of surgery (or matched control date). Non-responders were contacted up to two times by 
telephone to ascertain their consent. The RRS sub-study was approved by The University of Sydney 
Human Research Ethics Committee and institutional ethics committees at each recruitment site. 
 
Measures 
Socio-demographics: Age, marital (partner) status and education level were collected as part of the 
kConFab Psychosocial Study.  
Objective breast cancer risk: The relative risk of developing breast cancer by age 70, calculated using 
the Tyrer-Cuzick algorithm [25] at recruitment into kConFab [26], was obtained from kConFab. The 
estimate includes genetic, family history and other clinical and epidemiological risk factor data [27].  
Risk-reducing surgery: As part of the Psychosocial Study questionnaire assessment at each time point 
women answered two questions about RRS: “Would you consider a bilateral prophylactic 
mastectomy (an operation to remove both healthy breasts to prevent getting cancer)?” and “Would 
you consider a bilateral prophylactic oophorectomy (an operation to remove both healthy ovaries to 
prevent getting cancer)?” Response options were 1) Don’t know, 2) No, 3) Yes, and 4) Done/in 
progress.  Women who responded ‘Done/in progress’ were asked if they would be willing to answer 
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some questions related to having had RRS approximately three years after their surgery. Risk 
reducing surgery status was verified as part of the Psychosocial Study life event stress interviews, 
and/or from kConFab registry data. Women who had RRM were asked to indicate whether they had 
undergone breast reconstruction. 
Hormone Replacement Therapy (HRT): HRT use was documented by self-report questionnaire as part 
of the three year post-surgery assessment (or matched date for controls).  Questions about HRT use 
were: 1) Have you ever taken hormone replacement therapy (HRT)? Y/N, if yes; then 2) What age 
were you when you first took HRT? (Please estimate) ___ years old; 3) Are you still taking HRT? Y/N; 
if no, what age were you when you stopped HRT? (estimate is fine): ___ years old; and 4) Did you 
take HRT consistently (that is, with no breaks) from the time you started it until the time you 
stopped (or until now if you are still taking it)? Y/N. Responses were dichotomised into never or past 
use versus current use. 
 
Psychosocial variables (measured at baseline and at three years): 
a) Perceived breast and ovarian cancer risk: 
Perceived lifetime risks of developing breast and ovarian cancer were assessed on two 
numerical differential scales ranging from 0 (‘No chance’) to 100 (‘Definitely’) [28];  
b) Psychological well-being:  
Anxiety and depression were measured using the 14-item Hospital Anxiety and Depression Scale 
[HADS; 29], producing two separate scores ranging between 0-21. Cronbach’s alpha (α) was .82 
for anxiety and .78 for depression. 
Cancer-related anxiety was assessed by the 7-item Intrusive Thoughts subscale of the Impact of 
Event Scale [IES; 30], reflecting the frequency and severity of intrusive thoughts about ‘being at 
risk of developing breast cancer/ovarian cancer’ in the past week, with scores ranging from 0-35 
(α=.91). 
c) Body image, sexual functioning and menopausal symptoms (at three-year follow-up only):  
Body image: The affective aspect of body image was assessed using the 20-item short form of 
the Situational Inventory of Body Image Dysphoria [SIBID; 31]. This scale addressed the need for 
a body image scale that is applicable to women who had undergone RRM or RRO, as well as 
controls, and is suitable for use in the oncology setting as, unlike many other body image 
measures, it does not include weight-related body image concerns [32]. Scale scores reflect the 
mean of the 20 items (range 0-4), with higher scores reflecting poorer body image (α=.97).  
Sexual functioning: The nine-item Sexual Activity Questionnaire [SAQ; 33] was used to measure 
sexual functioning. Higher pleasure scores (range=0-18, α=.84) indicate greater desire, 
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enjoyment and satisfaction; lower discomfort scores (range=0-6, α=.80) reflect less dryness and 
pain; and the habit score (range=0-3) compares the current level of sexual activity with usual 
activity (0=much more, 1=somewhat more, 2=about the same, 3=less than usual). 
Menopausal symptoms: The Menopause Rating Scale [MRS; 34] evaluates 11 symptoms on a 
five-point scale (0=no symptoms, 4=severe) at three time points (‘before surgery’, ‘after 
surgery’ and ‘in the past month’). Since we focus on long-term outcomes in the current paper, 
only comparisons for menopause symptoms ‘in the past month’ are reported. Total MRS scores 
range between 0 (asymptomatic) and 44 (highest degree of complaints), with subscales for 
psychological symptoms (range 0-16), somato-vegetative symptoms (range 0-16) and urogenital 
symptoms (range 0-12, α=.85 for the total [current] scale). 
 
Changes in body image and decision regret (surgery participants only, three years post-surgery) 
Decision Regret Scale [DRS; 35]:  This five-item scale was used to assess the level of regret associated 
with the RRS decision. Potential scores range between 0-100 (α=.88), with higher scores reflecting 
greater regret. 
Body Image Scale [BIS; 36]: This 10-item scale was used to assess changes in body image since RRS. 
The BIS consists of 10 items scored on a 4-point scale (0-3), such that higher scores (range 0-30) 
represent increasing symptoms/distress (α=.92). 
 
Statistical analysis 
Descriptive statistics were used to characterize the sample. T-tests were used to compare RRS and 
control participants on the matching variables age and relative risk. Means and standard deviations 
for all outcomes were calculated for each of the groups. To identify potential confounders to be 
included in the analysis, differences between participants who had RRS and their respective controls 
in demographic and risk-related variables were analyzed using Chi-square for categorical variables 
and ANOVA for continuous variables. All subsequent analyses controlled for those variables found to 
differ between groups: age, objective risk of breast cancer, education and partner status.  
Generalized linear models (GLM) were employed to compare women who had had any 
surgery to controls while accounting for the correlation of responses within a matched cluster. 
Similarly, contrasts in GLM were constructed to compare each surgery group (RRM, RRSO and 
RRM+RRSO) to its respective control group, and to compare the surgery groups with each other 
(RRM vs RRSO; RRM vs RRM+RRSO; RRSO vs RRM+RRSO), while controlling for the correlation of 
responses within a matched cluster. HRT use (never or past use vs current use) was evaluated in the 
RRSO and RRM+RRSO groups for the SAQ and MRS outcomes using ANCOVA models. No significant 
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differences were observed in the SAQ or MRS outcomes according to HRT use (data not reported). 
Thus HRT was not controlled for in subsequent analyses. Stepwise logistic regression was used to 
assess whether poorer body image and/or sexual functioning were associated with decision regret in 
women who underwent surgery, with relative risk, age, partner status and education entered in the 
first step and scores on the BIS and SAQ subscales entered in the second step. Due to missing data, 
53 of the 70 surgery participants were included in this analysis, and as all 53 of these participants 
were partnered this variable was not included in the regression. Statistical significance was defined 
as p<.01 to account for the multiple pairwise comparisons for each outcome.   
 
RESULTS 
Participants 
The final sample (N=233) consisted of 17 women who had RRM (and 39 matched controls), 38 
women who had RRSO (and 94 matched controls) and 15 women who had RRM+RRSO (and 30 
controls). Of 76 eligible unaffected women who had had RRS and were contacted, 70 (92%) 
participated. Three women declined participation, two were not contactable and one was missed 
due to an administrative error. Of 233 eligible unaffected women who had NOT had RRS and were 
invited to participate, 163 (70%) participated. Sixty-three women declined participation and seven 
were not contactable. A flow diagram of study recruitment is presented in Figure 1. There were no 
differences between controls who participated versus those who refused on age, education or 
relative risk of breast cancer (data not shown).  
 At the time of the follow-up questionnaire, 60 women (26% of the sample) were aged under 
40 and 112 (48%) were aged 40 to 49, with the remainder aged 50 or over. The median relative risk 
of developing breast cancer was 3.7 (SD=10.3, range 0.71-65.7). Sixty percent of the women reported 
post-secondary education, and 85% were partnered. Demographic characteristics are reported 
separately for RRS participants and controls in Table 1. Of the 32 women who had RRM, 31 reported 
that they underwent reconstruction and the response to this item was missing for the other 
participant. 
 
Main Results 
Table 2 shows the means and standard deviations for all outcomes measured at baseline and follow 
up, including change scores, for the surgery groups and their respective controls, with statistical 
                                                
1 Relative risk of one RRS participant was calculated as 0.83 upon entry to kConFab. This participant is not 
eligible for predictive testing as no deleterious mutation has been identified in the family. Lower age at first 
child and older age at menarche are associated with relative risks of less than 1 [25]. 
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differences highlighted using * to indicate p<.05 and # to indicate p<.01. Table 3 shows results of 
statistical comparisons between different pairs of surgery groups.   
 
Women who underwent RRS of any type 
With regard to the control matching variables, women who had surgery did not differ from controls 
in age, but had significantly higher relative risks compared with controls, 10.94 vs 6.88, respectively  
(t[231]=-2.80, p=.006). Women who subsequently underwent either type of RRS reported 
significantly greater reductions in both perceived breast (p<.01) and ovarian cancer risk (p<.01) as 
well as cancer-related anxiety (p<.01) at the three-year follow up compared to the control group 
(Table 2).  Women who had RRS of any type reported significantly higher levels of sexual discomfort 
(SAQ, p<.01) and more urogenital symptoms (p<.01) compared to controls.  
 
Women who underwent RRM 
Women who subsequently underwent RRM reported higher perceived risk of breast cancer at 
baseline than their non-surgery controls (p<.01, Table 2). Perceived breast cancer risk was 
significantly reduced at the three-year follow up for women in the RRM group, compared to controls 
(p<.01, Table 2). At the three-year follow-up, perceived risk of breast cancer was significantly lower 
in the RRM group, compared with the RRSO group (p<.01, Table 3).   
Women who underwent RRM reported higher levels of cancer-related anxiety at baseline 
(p<.01) and greater reductions in cancer-related anxiety (p<.01) at the three-year follow up, 
compared to controls (Table 2). Women who underwent RRM also reported a greater reduction in 
cancer-related anxiety at the three-year follow up, compared to the RRSO group (p<.01, Table 3).  
 Women in the RRM group reported fewer total menopausal symptoms compared to the 
RRSO (p<.01) and the RRM+RRSO groups (p<.01) at the three-year follow up. Specifically, both 
psychological menopausal symptoms (p<.01) and urogenital menopausal symptoms (p<.01) were 
lower in the RRM compared to the RRSO group (Table 3). 
 
Women who underwent RRSO 
Women who subsequently underwent RRSO reported higher perceived ovarian cancer risk at 
baseline compared with women who subsequently underwent RRM (p<.01, Table 3). Perceived 
ovarian cancer risk was significantly reduced at the three-year follow up for women who had RRSO 
compared to controls (p<.01, Table 2). Women who had RRSO also reported larger reductions in 
perceived ovarian cancer risk from baseline to three-year follow up compared with women who only 
had RRM (p<.01, Table 3). By contrast, reductions in perceived risk of breast cancer at the three-year 
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follow-up were significantly lower in the RRSO group, compared with the RRM group (p<.01) and the 
RRM+RRSO group (p<.01, Table 3).   
 Women in the RRSO group reported more sexual discomfort (p<.01) and urogenital 
symptoms (p<.01), compared to controls (p<.01, Table 2).  Surprisingly, women who had RRSO did 
not report significantly more menopausal symptoms overall at the three-year follow up compared 
with their controls, although these differences approached significance (p=.018, Table 2). 
 
Women who underwent RRM+RRSO 
Both perceived breast (p<.01) and ovarian cancer risk (p<.01) were significantly reduced at the 
three-year follow up for women who had RRM+RRSO, compared to controls (Table 2). At the three-
year follow-up, perceived risk of breast cancer was significantly lower in the RRM+RRSO group, 
compared with the RRSO group (Table 3). Women who had RRM+RRSO reported larger reductions in 
perceived ovarian cancer risk from baseline to three-year follow up compared with women who only 
had RRM (p<.01, Table 3). 
Women who had RRM+RRSO reported more urogenital symptoms compared to their 
controls (p<.01, Table 2). Perhaps surprisingly, women who had RRM+RRSO did not report 
significantly more menopausal symptoms overall at the three-year follow up compared with their 
controls, although these differences approached significance (p=.011, Table 2).   
 
General anxiety, depression and body image  
No differences in baseline or changes scores were observed in levels of anxiety, depression or body 
image (SIBID) for: 1) any of the surgery groups compared to controls, and 2) between surgery 
groups. No differences in body image (BIS) scores were observed between surgery groups. 
 
RRS decision regret 
As the scores were highly skewed towards no regret, with almost two-thirds (62.9%) of the 
participants reporting no regret about their RRS decision, scores were dichotomized as no regret 
(score=0) vs any regret (score=1-100). No differences were observed in decisional regret between 
the surgery groups (X2[2, N=70]=4.82, p=.09). However, women who reported greater reductions in 
body image (BIS) following surgery (OR=1.41, 95%CI=1.11-1.78, p<.01) were more likely to report 
feeling at least some regret. The Hosmer and Lemeshow Test supported the goodness of fit of the 
model (X2 [8, N=53]=5.64, p=.69), which explained approximately 19% of the variation in decisional 
regret (Nagelkerke R2 =.19). 
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Discussion 
 
This study prospectively compared psychological well-being and risk perceptions of women at 
increased risk of HBOC who underwent RRS to a group of control participants, matched for age and 
objective risk. Differences between the groups in sexual functioning, body image and menopausal 
symptoms were also investigated. The results of this study suggest there are few negative long-term 
impacts of RRS.  
Consistent with past research [7,10,6], women who opted for RRS experienced psychological 
benefits, namely reductions in perceived risk and cancer-related anxiety, compared with controls.  
However, cancer-related anxiety was higher in the RRS group at baseline, supporting previous 
findings that elevated cancer-related anxiety predicts uptake of RRS [6]. At follow up, levels of 
cancer-related anxiety reported by women who had undergone RRS were not significantly different 
to controls. This suggests that while RRS may effectively reduce cancer-related anxiety, it only 
reduces it to a level that is comparable with other at-risk women who have not undergone RRS. In 
addition, based on the current findings, RRS may only reduce cancer-related, but not general, 
anxiety. The baseline assessment time point in the current study (at a time of usual functioning, 
versus before screening when anxiety is usually elevated) may explain why the reductions in general 
anxiety following RRS that have been reported in previous studies [19,21] were not replicated. 
Further prospective studies using baseline data that reflects usual functioning are needed to clarify 
this.  
In this study, RRS appeared to have minimal long-term impacts on body image and sexual 
functioning. Although RRSO has not previously been shown to negatively impact body image [37], 
past research has concluded that women who undergo RRM report worse body image after surgery 
[21,10,22]. We considered whether the high rate of reconstruction in our sample may explain these 
differences; however, 95-100% of participants in these previous studies had also undergone 
reconstruction.  
The discrepancy between those studies and findings of the current study may be explained 
by the longer follow-up and comparison to a matched sample in the present research. In other 
words, women’s body image may take a few years to adjust following surgery; eventually their 
actual levels of body image may be similar to those of other high-risk women.  
However, there may be limitations associated with the measure used in the current research 
which resulted in insufficient sensitivity to the concerns of the women in this study. The Body Image 
Scale assessed changes in body image since surgery retrospectively and it is possible that the 
retrospective assessment biased women’s responses. In addition, the Body Image Scale measured 
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general body image and a measure of breast-related body image may have yielded different results 
for the women who underwent RRM.  
In a study of long-term outcomes of RRM, den Heijer et al. [38] investigated body image in 
36 women prior to risk-reducing mastectomy (T0) then again at six months (T1) and six to nine years 
(T2) post-surgery. All participants underwent breast reconstruction. These authors found a 
significant deterioration from T0 to T1 in both general and breast-related body image. They 
observed a non-significant improvement in general body image scores from T1 to T2, concluding 
that, overall, general body image was worse in the longer term. However, based on the data 
presented in the paper, we calculate that the overall (T0 to T2) deterioration in general body image 
was not significant (t[35]=-1.39, p=.17). This is consistent with our finding in the present research 
that women do not experience significant long-term reductions in body image following RRM.  
Interestingly, den Heijer et al. [38] reported that, following the initial deterioration in breast-
related body image, there was a significant improvement between T1 and T2. However we calculate 
that the overall deterioration in breast-related body image from T0 to T2 is, in fact, significant 
(t[35]=-2.57, p=.01). Thus when a breast-specific measure of body image is used, significant 
deteriorations in body image can be seen in women who undergo RRM. The use of non-specific 
measures of body image in the current study can be considered a limitation and future studies 
should aim to measure breast- and ovary-specific components of body image.  
Sexual discomfort and urogenital menopausal symptoms were worse in women who had 
RRS compared to controls, but subgroup analyses revealed these differences were only present for 
women who had undergone RRSO or both surgeries, which would be expected to cause menopausal 
symptoms. These findings are consistent with previous studies [7,16]. However, it is reassuring that 
the discomfort and urogenital symptoms reported in the present research did not appear to 
interfere substantially with psychosexual (e.g. pleasure, habit) aspects of sexual functioning. 
Although there is evidence that sexual dysfunction is associated with satisfaction with RRSO [16], 
further research is needed to explore specific predictors of sexual functioning following RRS. It is 
surprising that menopausal symptoms were not affected by HRT use in the current study, but the 
small subgroups in this comparison may have compromised statistical power in this analysis. 
Consistent with past research [13], women who experienced a greater deterioration in body 
image following surgery were more likely to report some level of regret. Despite the difficulties in 
sexual function and increased menopausal symptoms following RRSO, the level of regret was low in 
this sample, and this supports the hypothesis that reductions in perceived risk and cancer-related 
anxiety outweigh any regret related to adverse outcomes [15]. Nevertheless, the findings of this 
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study support the need to foster realistic expectations about potential sexual dysfunction and 
menopausal symptoms in women considering RRSO. 
A number of limitations should be considered when interpreting the findings of this study. 
First, the relatively small sample size resulted in small subgroups and thus limited statistical power to 
detect differences between the groups. Many women had undergone RRS pre-baseline and were 
thus not eligible for inclusion in this prospective study. Further, there were few women with high 
relative risks who had not undergone RRS available for matching to surgery participants and thus 
matching on relative risk was imperfect. Second, while perceived risk and psychological variables 
were assessed prospectively, body image, sexual functioning and menopausal symptoms were 
assessed retrospectively. However the inclusion of matched controls for comparison on these (and 
other) variables is a significant strength of this study, as is the consistent three-year follow-up 
period. This is the first long-term, matched-control, prospective study of outcomes of RRS. The 
findings demonstrate that although menopausal symptoms and sexual discomfort persist three 
years post-surgery for women who underwent RRSO, the overall psychosocial impact is minimal. 
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Table 1. Baseline participant characteristics 
__________________________________________________________________________________ 
      RRS  Control  Whole 
      groups  groups  sample 
      n = 70  n = 163  n = 233 
      n (%)  n (%)  n (%)  
Age (years) 
   <40      17 (24.3) 43 (26.4) 60 (25.8) 
   40-49      35 (50.0) 77 (47.2) 112 (48.1) 
   50-59      12 (17.1) 32 (19.6) 17 (7.3) 
   60+      6 (8.6)  11 (6.7)  17 (7.3) 
Educational level 
   High school or less    28 (40.6) 62 (39.2) 90 (39.6) 
   Post-secondary education   41 (59.4) 96 (60.8) 137 (60.4) 
Partner Status   
   No partner      8 (11.6)  27 (16.6) 35 (15.1) 
   Partnered     61 (88.4) 136 (83.4) 197 (84.9) 
Carrier status 
   Knows is BRCA1/2 positive   19 (27.1) 13 (8.0)  32 (13.7) 
   BRCA1/2 negative/Inconclusive/Not tested  
Relative Risk (Breast Cancer) 
   < 1.5      5 (7.1)  9 (5.5)  14 (6.0) 
   1.5-3      20 (28.6) 65 (39.9) 85 (36.5) 
   3-5      12 (17.1) 32 (19.6) 44 (18.9) 
   5-10      8 (11.4)  30 (18.4) 38 (16.3) 
   10+      25 (35.7) 27 (16.6) 52 (22.3) 
Type of surgery or group 
controls were matched to 
   RRM      17 (24.3) 39 (23.9) N/A 
   RRSO      38 (54.3) 94 (57.7) N/A 
   RRM&RRSO     15 (21.4) 30 (18.4) N/A 
Perceived risk    
   Breast cancer M(SD)    60.4 (25.5) 52.5 (26.6) 54.8 (26.5) 
   Ovarian cancer M(SD))   40.4 (27.3) 32.5 (22.7) 34.8 (24.4) 
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Table 2. Comparisons between surgery groups and their respective controls on perceived risk, anxiety, depression, cancer-related anxiety, body image, sexual 
functioning and menopausal symptoms 
         RRM (n=17)     Controls (n=39)                RRSO (n=38)       Controls (n=94)                    RRM+RRSO (n=15) Controls (n=30) 
M(SD)  M(SD)            M(SD)  M(SD)                M(SD)  M(SD) 
Perceived risk of breast cancer 
 Baseline  71.3 (15.9) 52.6 (24.9)#   56.9 (26.1) 53.8 (27.1)    57.3 (30.3) 48.0 (27.6) 
 Follow-up  13.5 (13.8) 52.8 (26.3)   52.7 (18.8) 53.3 (27.4)   11.3 (14.6) 52.9 (26.5) 
 Change scores   -57.5 (20.7) 0.3 (20.3)#   -4.2 (27.5) -0.5 (23.7)   -46.0 (37.9) 2.1 (21.3)# 
Perceived risk of ovarian cancer 
 Baseline   32.2 (15.6) 32.6 (26.4)   42.0 (29.3) 31.8 (21.7)   45.3 (31.4) 34.3 (21.3) 
 Follow-up  26.2 (18.3) 34.6 (23.8)   1.2 (3.2) 32.8 (23.5)   10.7 (22.2) 40.4 (25.3) 
 Change scores   -5.0 (18.9) 2.1 (20.7)   -40.8 (28.8) 0.9 (22.5)#   -34.7 (29.0) 4.3 (22.8)# 
HADS-Anxiety 
 Baseline   6.6 (3.4)  6.1 (3.3)    6.3 (4.1)  5.8 (3.8)    6.5 (4.6)  5.9 (3.0) 
 Follow-up  5.6 (3.0) 5.5 (3.8)   5.9 (3.4) 5.8 (3.4)   5.9 (3.5) 5.5 (3.5) 
 Change scores  -1.1 (2.6) -0.6 (2.9)   -0.4 (3.6) -0.1 (3.3)   -0.5 (3.4) -0.4 (2.6) 
HADS-Depression 
 Baseline  3.5 (3.0) 3.2 (3.1)   3.6 (2.9) 3.9 (3.4)   4.1 (3.2) 3.5 (2.6) 
 Follow-up  2.2 (2.2) 3.1 (2.9)   2.9 (2.8) 3.5 (3.4)   3.3 (2.4) 3.0 (2.4) 
 Change scores  1.2 (2.4) -0.2 (2.7)   -0.7 (2.4) -0.4 (3.4)   -0.8 (2.9) -0.5 (2.5) 
Cancer-related anxiety 
 Baseline  13.4 (8.3) 4.5 (5.9)#   6.5 (7.1) 4.7 (6.7)   9.2 (10.1) 7.8 (8.2) 
 Follow-up  6.2 (6.9) 4.1 (6.8)   4.5 (6.8) 4.6 (7.0)   3.0 (5.1) 5.1 (7.1) 
 Change scores  -7.2 (9.3) -0.5 (8.0)#   -1.9 (6.4) -0.1 (6.0)   -6.0 (7.7) -2.7 (7.2) 
Body image (SIBID) 1.3 (1.1) 1.3 (1.0)   1.5 (1.1) 1.4 (0.9)   1.3 (0.7) 1.3 (0.7) 
SAQ Pleasure  13.1 (4.1) 12.1 (4.3)   11.5 (4.8) 12.0 (4.1)   9.3 (5.3)  13.3 (2.4)* 
SAQ Discomfort  1.1 (1.5) 1.1 (1.7)   2.4 (2.0) 1.0 (1.4)#   2.5 (2.1) 1.4 (1.6)* 
SAQ Habit  0.9 (0.4) 0.7 (0.5)   0.9 (0.5) 0.9 (0.6)   0.8 (0.6) 1.1 (0.5) 
MRS Total  4.1 (5.5) 6.4 (6.1)   11.3 (8.3) 8.5 (5.5)*   10.4 (5.5) 7.3 (5.2)* 
MRS Psychological 1.9 (2.4) 3.3 (3.0)   3.8 (3.4) 3.9 (2.9)   2.9 (2.5) 3.4 (2.8) 
MRS Somato-vegetative 1.5 (1.8) 1.7 (2.1)   4.0 (3.3) 3.1 (2.6)   3.4 (2.6) 2.9 (2.2) 
MRS Urogenital  0.9 (1.9) 1.3 (1.7)   3.4 (2.7) 1.5 (1.6)#   3.6 (2.1) 0.9 (1.1)# 
*p<.05; #p< .01; SIBID=Situational Inventory of Body Image Dysphoria; SAQ=Sexual Activity Questionnaire; MRS=Menopause Rating Scale  
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Table 3. Comparisons between surgery groups on perceived risk, anxiety, depression, cancer-related anxiety, body image, sexual functioning, menopausal 
symptoms and change in body image after surgery 
       RRM (n = 17)        RRSO (n = 38)       RRM+RRSO (n = 15)    Surgery Comparison p-values 
M(SD)       M(SD)   M(SD)       RRM vs RRSO   RRM vs RRM+RRSO    RRSO vs RRM+RRSO  
Perceived risk of breast cancer 
 Baseline  71.3 (15.9)  56.9 (26.1)  57.3 (30.3)    .32  .54  .98 
 Follow-up  13.5 (13. 8)  52.7 (18.8)  11.3 (14.6)   <.01  .01  <.01 
 Change scores  -57.5 (20.7)  -4.2 (27.5)  -46.0 (37.9)   <.01  .18  <.01 
Perceived risk of ovarian cancer 
 Baseline  32.2 (15.6)  42.0 (29.3)  45.3 (31.4)   <.01  .02  .76 
 Follow-up  26.2 (18.3)  1.2 (3.2)  10.7 (22.2)   <.01  .34  .05 
 Change scores  -5.0 (18.9)  -40.8 (28.8)  -34.7 (29.0)   <.01  <.01  .43 
HADS-Anxiety 
 Baseline  6.6 (3.4)   6.3 (4.1)  6.5 (4.6)   .80  .90  .93 
 Follow-up  5.6 (3.0)  5.9 (3.4)  5.9 (3.5)   .33  .36  .88 
 Change scores  -1.1 (2.6)  -0.4 (3.6)  -0.5 (3.4)   .46  .54  .98 
HADS-Depression 
 Baseline  3.5 (3.0)  3.6 (2.9)  4.1 (3.2)   .48  .33  .60 
 Follow-up  2.2 (2.2)  2.9 (2.8)  3.3 (2.4)   .10  .07  .61 
 Change scores  -1.2 (2.4)  -0.7 (2.4)  -0.8 (2.9)   .52  .71  .91 
Cancer-related anxiety 
 Baseline  13.4 (8.3)  6.5 (7.1)  9.2 (10.1)   .01  .28  .39 
 Follow-up  6.2 (6.9)  4.5 (6.8)  3.0 (5.1)   .97  .47  .36 
 Change scores  -7.2 (9.3)  -1.9 (6.4)  -6.0 (7.7)   <.01  .43  .07 
Body image (SIBID) 1.3 (1.1)  1.5 (1.1)  1.3 (0.7)   .30  .56  .58 
SAQ Pleasure  13.1 (4.1)  11.5 (4.8)  9.3 (5.3)   .12  .01  .12 
SAQ Discomfort  1.1 (1.5)  2.4 (2.0)  2.5 (2.1)   .05  .12  .99 
SAQ Habit  0.9 (0.4)  0.9 (0.5)  0.8 (0.6)   .87  .35  .38 
MRS Total  4.1 (5.5)  11.3 (8.3)  10.4 (5.5)   <.01  <.01  .56 
MRS Psychological 1.9 (2.4)  3.8 (3.4)  2.9 (2.5)   <.01  .10  .26 
MRS Somato-vegetative 1.5 (1.8)  4.0 (3.3)  3.4 (2.6)   .02  .16  .39 
MRS Urogenital  0.9 (1.9)  3.4 (2.7)  3.6 (2.1)   <.01  <.01  .82 
Body image (BIS) 8.2 (8.0)  4.9 (5.9)  8.2 (7.9)   .66  .11  .09 
SIBID=Situational Inventory of Body Image Dysphoria; SAQ=Sexual Activity Questionnaire; MRS=Menopause Rating Scale; BIS=Body Image Scale 
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Figure 1. Surgery and control participation flow diagram 
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